CLL.L Regulatory News (CLL)

Cello Group plc

(the "Group" or the "Company")

Healthcare Seminar:

Pharmaceuticals and Health, a Sustainable Sector for Advisory Services

Cello, the leading insight and strategic marketing group, is later today holding a meeting for analysts and investors at which the executive team will provide an update on the Group's Healthcare opportunity and the audience will hear from two leading Healthcare guest speakers - Stephen Whitehead, Chief Executive of the Association of the British Pharmaceutical Industry and Janis Clayton who is General Manager for Shire's Human Genetic Therapies Division.

The purpose is to provide an opportunity to understand not only the importance of the Pharmaceutical sector, but why there is a structural need to work with external partners like Cello. The event will focus on the importance of the industry to governments around the world and the key challenges the industry faces for clients and service providers.

Guest Speakers

Stephen Whitehead is Chief Executive of the Association of the British Pharmaceutical Industry. Stephen's most recent role was Group Communications Director at Prudential PLC and he has previously held senior leadership roles at Barclays PLC and Allied Domecq PLC. He has a strong personal passion and commitment to the Pharmaceutical industry and earlier in his career spent ten years at Glaxo and Eli Lilly at UK, European and International level. Stephen has in-depth experience of working in regulated industries.

Janis Clayton is General Manager of a region encompassing UK, Ireland, Scandinavia, Finland and Baltics for Shire's Human Genetic Therapies Division. Shire is a global Pharmaceutical company with products marketed in over 50 countries worldwide and offices in 29 countries. Shire HGT focus on developing treatments for extremely rare and life-threatening disease like Hunter Syndrome or Fabry Disease as well as for specialist conditions including ADHD and ulcerative colitis. During her career Janis has worked in research, commercial and general management roles, primarily in very specialised therapy areas.

Cello Group recently announced that Cello's Pharmaceutical businesses will be grouped under a single structure "Cello Health". The Senior Cello Health team, and Cello Group CEO Mark Scott, will also be presenting and discussing the Group's expert capabilities in this key sector. No material new information will be disclosed during the day.

For further Information please contact: